
To investigate the association between treatment with dulaglutide and glycaemic variability (GV) in adult patients with type 2 diabetes mellitus (T2D).Post hoc analyses of six randomized, phase 3 studies were conducted to investigate the association between treatment with dulaglutide 1.5 mg once weekly and GV in adult patients with T2D. Using data from seven‐ and eight‐point self‐monitored plasma glucose (SMPG) profiles over up to 28 weeks of treatment, GV in within‐ and between‐day SMPG, and between‐day fasting glucose from SMPG (FSMPG) was assessed according to standard deviation and coefficient of variation. Pooled data from five studies with dulaglutide as monotherapy or added to oral glucose‐lowering medication, without concomitant insulin treatment, revealed clinically meaningful reductions in within‐ and between‐day SMPG, and between‐day FSMPG variability from baseline in the dulaglutide group...
Like
Save
Share